GCCL develops Korea's first automatic clinical trial data sharing system

Automatic data-sharing system will prevent human errors and improve expertise in clinical trial sample analysis

GCCL develops Korea's first automatic clinical trial data sharing system
Ji-Hyun Lee 1
2023-01-10 13:53:47 bluesky@hankyung.com
Bio & Pharma

Global Clinical Central Lab (GCCL), an affiliate of South Korean pharmaceutical firm Green Cross Corp., said on Monday it has jointly developed Korea's first clinical trial automatic data-sharing system with CRScube, a company specializing in clinical software solutions.

GCCL is a Good Clinical Laboratory Practice (GCLP)-certified agency of the Ministry of Food and Drug Safety of South Korea and is a clinical trial sample analysis company that provides services for all phases of clinical trials from phase 1 to 4.

Through this joint development, GCCL will be able to provide customers with fast and accurate clinical analysis results by linking its clinical trial project management system G-HUB with CRSCube's electronic data capture solution cubeCDMS.

G-HUB allows a real-time verification of clinical trial samples from transportation to analysis and reporting results, while cubeCDMS is a software program that collects and integrates data on the entire cycle of clinical trials.

"We hope that the automated data sharing system will replace existing manual tasks to prevent human errors and improve expertise in clinical trial sample analysis," an official of GCCL said.

Write to Ji-Hyun Lee at bluesky@hankyung.com

Green Cross' two Kosdaq-listed cell therapy arms to merge

Green Cross' two Kosdaq-listed cell therapy arms to merge

Green Cross's Hwasun factory in South Jeolla Province, South Korea South Korea's pharmaceutical group Green Cross Corp., or GC Pharma, will combine its two cell therapy developers listed on the junior Kosdaq market in efforts to scale up and sharpen its focus on the growing cell-based therapy m

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross in talks with Russia to produce COVID-19 vaccine

Green Cross employees at Hwasun factory (Courtesy of Green Cross)  South Korea’s pharmaceutical company Green Cross Corporation (GC) is holding a series of close meetings on contract manufacturing of Russia’s COVID-19 vaccine CoviVac, according to industry sources on Mar. 17. C

(* comment hide *}